What To Expect From Repros (RPRX) This Earnings Season
Zacks Investment Research | Nov 04, 2016 04:37AM ET
Repros Therapeutics Inc. (NASDAQ:RPRX) is expected to report third-quarter 2016 results on Nov 14. The company has reported an average positive surprise of 24.56% in the last two quarters. Let’s see how things are shaping up for this quarter.
Factors at Play
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to keep an eye on pipeline-related updates by the company. Repros’ pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros’ pipeline is enclomiphene, which is currently under review in the EU. The company is looking to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Meanwhile, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with a routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Also, Repros plans to hold a discussion with the FDA regarding the prospects of advancing Proellex into phase III studies for the treatment of women struggling with painful menstruation. In addition, Proellex is being evaluated for the treatment of uterine fibroids.
Repros currently carries a Zacks Rank #3 (Hold).
Stocks that Warrant a Look
Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements – a positive Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.